Received Mar 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 3 | Y018389 | — |
No additional AE; HCP called to report a patient received a third dose of GARDASIL 9 after competition of the two-dose series on February 19, 2019. No side effects or symptoms reported. No additional information provided. No Additional AE/ No PQC.; This spontaneous report was received from medical assistant and refers to 16-year-old male patient. The patient's medical history was not reported. His drug history included Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9). The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 28-FEB-2025, the patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), (valid lot #Y018389, expiration date: 04-NOV-2026) 0.5 mL. On 28-FEB-2025, the patient received a third dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL9) after competition of the two-dose series on 19-FEB-2019. No side effects or symptoms reported. No additional information provided. No Additional AE/ No PQC.. On an unknown date, the patient experienced No additional AE. At the reporting time, the outcome of HCP called to report a patient received a third dose of GARDASIL 9 after competition of the two-dose series on February 19, 2019. No side effects or symptoms reported. No additional information provided. No Additional AE/ No PQC. and No additional AE was unknown. The action taken with Human Papillomavirus 9-valent Vaccine, Recombinant was reported as not applicable.